New Anti-Mesothelioma Antibody and Biomarker Discovered
|

New Anti-Mesothelioma Antibody and Biomarker Discovered

Dr. Tsuji is working on discovering specific cancer antigens for malignant mesothelioma. A new study from the Gunma University of Health and Welfare shows a new anti-mesothelioma antibody for the diagnosis and treatment of mesothelioma. The use of antibody drugs is becoming more popular in the treatment of mesothelioma. Antibody drugs are immunotherapy treatments. They recruit your body’s germ-fighting immune system to fight against mesothelioma. One the of biggest problems with mesothelioma immunotherapy is a lack of biomarkers. Mesothelioma is Difficult to Diagnose and Treat with Biomarkers Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Malignant mesothelioma is characterized by poor prognosis and short survival. Malignant mesothelioma is considered a treatment-resistant (intractable) cancer. Clinicians and researchers…

Monoclonal Antibody a ‘Novel Treatment’ for Mesothelioma?
| |

Monoclonal Antibody a ‘Novel Treatment’ for Mesothelioma?

A drug currently used to treat colorectal cancer and some types of head and neck cancer may also offer a new way to combat mesothelioma. Malignant pleural mesothelioma is an asbestos-linked cancer that spreads across the mesothelial tissue surrounding the lungs. The disease is highly resistant to most conventional therapies and is often fatal within a year of diagnosis.  As the number of mesothelioma cases continues to increase in many developing counties, scientists around the world are studying mesothelioma cells for clues that could help them develop more effective treatments. One clue is the overexpression of epidermal growth factor receptor (EGFR). EGFR is overexpressed by mesothelioma cells and several other types of cancer cells. The monoclonal antibody cetuximab, which is derived…